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Background: To evaluate the efficacy and toxicity of fractionated stereotactic radiotherapy (FSRT) in patients with
residual nasopharyngeal carcinoma (NPC).
Methods: From January 2000 to December 2009, 136 NPC patients with residual lesions after primary radiotherapy
(RT) were treated by FSRT. The total dose of primary RT was 68.0-78.0 Gy (median, 70.0 Gy). The median time from
the primary RT to FSRT was 24.5 days. Tumor volumes for FSRT ranged from 0.60 to 77.13 cm3 (median, 13.45 cm3).
The total FSRT doses were 8.0-32.0Gy (median, 19.5 Gy) with 2.0-10.0 Gy per fraction.
Results: Five-year local failure-free survival (LFFS), freedom from distant metastasis (FFDM), overall survival (OS), and
disease free survival (DFS) rates for all patients were 92.5%, 77.0%, 76.2%, and 73.6%, respectively. No statistical
significant differences were found in LFFS, DFS and OS in patients with stage I/II versus stage III/ IV diseases.
Nineteen patients exhibited late toxicity. T stage at diagnosis was a significant prognostic factor for OS and DFS.
Age was a prognostic factor for OS.
Conclusion: FSRT after external beam radiotherapy provides excellent local control for patients with residual NPC.
The incidence of severe late toxicity is low and acceptable. Further investigation of optimal fractionation regimens
will facilitate reduction of long-term complications.
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ToxicityBackground
Nasopharyngeal carcinoma (NPC) is a radiosensitive
neoplasm, and definitive radiotherapy (RT) remains the
mainstay of treatment for NPC [1-7]. Although early-
stage NPC is highly curative by radiotherapy alone,
treatment results of loco regional advanced NPC remain
disappointing. Local residual rate of NPC is about 10%
and local recurrent rate ranges from 16.8% to 23%, de-
pending on the initial tumor status [4-6]. Various me-
thods have been used to improve local control (LC) of
late stage NPC (UICC Stage III/IV), including concur-
rent chemo radiotherapy, high-dose IMRT with radio* Correspondence: 13811026919@163.com; guozhenxu@vip.sina.com
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reproduction in any medium, provided the orsensitization, and intracavitary brachytherapy [2,8-11].
The outcome of salvage treatment for local recurrence is
poor, with a 5-year overall survival (OS) of 9.4–30%, and
a high risk of complications [12-15]. Proper salvage radi-
ation therapy is beneficial to achieve local control and
improve survival of residual NPC, but it may increase
therapy-related complications because of high doses of
irradiation to normal tissues. Fractionated stereotactic
radiotherapy (FSRT) or stereotactic radiosurgery (SRS)
as a boost treatment for residual NPC is effective with
improved local control and decreased complications.
There were studies on using FSRT or SRS for local re-
sidual NPC, but the numbers of patients were relatively
low or the follow-up time was limited [10,16]. Here
we report our long-term outcomes and late toxicitiesThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Characteristics of NPC patients with residual

















Conventional EBRT 85 (62.5%)
IMRT 51 (37.5%)
EBRT dose (Gy) Median 70 (range: 68.0–78.0)
Sites of local residual †
pharyngonasal cavity 116 (85.3)
parapharyngeal space 53 (40.0)
retropharyngeal lymph nodes 26 (19.1)
cavernous sinus 1 (0.7)
* According to 2002 UICC staging system.
† Sixty patients had more than one site of residual disease.
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disease.
Methods
This study was approved by the ethics committee of
Cancer Institute and Hospital, Chinese Academy of
Medical Sciences and Peking Union Medical College.
Patients’ characteristics
From January 2000 to December 2009, FSRT was ad-
ministered to 136 NPC patients who had local residual
lesions after the first course of external beam radiother-
apy (EBRT). Pretreatment evaluation for all the patients
included a complete history and physical examination,
flexible fiberoptic nasopharyngolaryngoscopy, initial
pathologic diagnosis, and multidisciplinary tumor board
discussion. Staging evaluations included chest radio-
graphs, complete blood count, complete metabolic panel,
and MRI with gadolinium and/or CT with contrast from
the base of skull to 2 cm below the clavicles. In selected
patients with T3-T4 tumor or N2-N3 neck nodal disease,
bone scans and chest and abdominal CT scans were also
obtained.
Inclusion criteria for this study were as follows: pa-
thological confirmation for all primary tumors prior
to EBRT; existence of local residual tumor after EBRT
and absence of distant metastasis. Residual tumor was
defined as residual disease by fibroendoscopy or MRI
within one week after completion of definitive EBRT.
The criteria for residual disease on MRI were persistent
tumor mass, thickened nasopharyngeal walls with en-
hancement at the primary site, or persistent enhancing
retropharyngeal lymph nodes that were present before
EBRT. If persistent lesion was observed by fibroendos-
copy, tissue biopsy was not always necessary due to the
risks of complications. If a superficial lesion in nasopha-
rynx or adjacent area did not meet the diagnostic criteria
of residual tumor on imaging studies, tissue biopsy is re-
quired within one week after imaging studies. Contrain-
dications for biopsy were as follows: deep lesions that
were located in parapharyngeal space, skull base, ca-
vernous sinus or any areas that were not easily acces-
sible; lesions abutting neurovascular tissues, evidence of
infection or ulcer in nasopharynx, hemorrhagic ten-
dency, or age older than 60 years or diabetes mellitus
that cause healing delays. For the patients with sus-
picious residual lesions on imaging studies but tissue
biopsy was contraindicated, we would repeat imaging
studies at one month from completion of EBRT, using
the same criteria for persistent disease described above.
Residual Sites in this study included nasopharyngeal ca-
vity, parapharyngeal space, retropharyngeal lymph nodes
or intracranial residual lesions, while cervical nodes were
not included. The patients with local residual tumor ofNPC were evaluated jointly by a team of head-and-neck
surgeons and clinical oncologists for possible salvage
treatment. FSRT was recommended to these patients if
it was considered the best available and acceptable treat-
ment option. All patients were staged according to the
2002 International Union against Cancer (UICC) staging
system. The twenty-five patients treated before 2002
were re-staged according to 2002 UICC staging system
for the purpose of this study. Seventy-six patients
(55.9%) had a single residual lesion, whereas 60 patients
(44.1%) had multiple lesions, thus, a total of 196 lesions
were treated by FSRT. All residual lesions were persist-
ent in the high dose regions of EBRT. The main sites of
local residual lesions were the pharyngonasal cavity, and
the parapharyngeal space. Thirty-two (29%) patients also
had skull base destruction. The details of the patient
characteristics are shown in Table 1.
Primary external beam radiotherapy
In 85 patients, conventional EBRT was delivered at 2 Gy
daily fractions, 5 fractions per week, to a median total
Figure 1 Isodose distribution using FSRT for residual disease
at nasopharynx.
Table 2 Summary of FSRT parameters
Parameters
Tumor volume (cm3) 13.45 (0.60–77.13)
Total prescribed dose (Gy) 19.5 (8.0–32.0)
Fractional dose (Gy)
>5 Gy 33 (24.3)
≤5 Gy 103 (75.7)
Fraction number 5 (2–8)
Time to FSRT after EBRT (days) 24.5 (2–147)
FSRT type
Collimator based 105 (77.2)
MLC based 31 (22.8)





Abbreviations: Values are median (range) or number (percentage).
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dominantly of opposed parallel lateral ports, and all
fields were treated with 6 MV beam photon. The lower
neck was treated with an appositional anterior cervical
field to 50 Gy. A block was used to protect the spinal
cord at the field junctions for all patients. Fifty-one pa-
tients received intensity-modulated radiotherapy (IMRT)
as the primary treatment of NPC. The gross tumor
vo lume (GTV) with margin for daily positioning uncer-
tainty was treated with 2.12-2.24 Gy fractions to a me-
dian total of 73.92 Gy (range, 69.96-78.0 Gy). The
clinical target volume (CTV) at high risk for microscopic
tumor involvement received 60.06 Gy in 30 fractions,
and the low-risk CTV received 50.96 Gy in 30 fractions.
All EBRT doses were limited to ≤40 Gy to the spinal
cord dose, ≤54 Gy to the optic apparatus, and ≤54 Gy to
the surface of the brainstem. The median overall time
for EBRT was 50 days (range, 46–68). Seventy-five
(71.4%) out of 105 patients with stage III/IV received
cisplatin-based concurrent chemoradiotherapy. Thirty pa-
tients with stage III/IV cancer did not receive chemotherapy
because of poor tolerance (such as severe comorbidities,
low Karnofsky performance score) or being treated with RT
alone on an institutionally randomized clinical trial.
FSRT technique and treatment
FSRT was performed using a collimator-based system
(Creat Stereotactic treatment system, China) with a
6-MV linear accelerator (Varian, USA) before July 2006,
and multileaf collimator (MLC)-based FSRT system
(BrainLAB, Germany) since August 2006. Patients were
immobilized using a relocatable-type head ring with a
wrapping head-band and stereotactic frame. Contrast-
enhanced CT scan with a slice thickness of 3 mm was
performed for treatment planning. If needed, MRI im-
ages were used to aid target delineation. The target vol-
ume was defined as abnormal soft-tissue mass or/and
contrast-enhanced areas as shown in axial images plus a
2–3 mm margin. Adjacent mucosal and soft tissues were
included if residual lesions were seen on flexible naso-
pharyngoscopy exam. Critical structures including brain-
stem, spinal cord, optic chiasm, optic nerves, eyeballs,
and lenses were contoured.
The fractional dose of FSRT was 2.0-10.0 Gy (median,
4.0 Gy) per fraction. The number of isocenters ranged
from 1 to 3 (median, 1). Thirty-three patients received
FSRT with fractionated dose>5 Gy, including 16-20Gy/
8-10Gy/2f for 3 patients, 20-26Gy/6-8Gy/3-4f for 5 pa-
tients, 18-26Gy/5.2-7Gy/3-5f for 25 patients; and 103
patients received FSRT with fractionated dose≤5 Gy, in-
cluding 12-32Gy/4-5Gy/3-8f for 49 patients, 8-23Gy/
2-3.5Gy/3-7f for 54 patients. An example of isodose dis-
tribution is shown in Figure 1. To compare various frac-
tionation schemes, the biologically effective dose (BED)was calculated using the equation BED=total dose×(1+d/
α/β), where d=dose per fraction and α/β=10, no correc-
tion was made for tumor proliferation since all the treat-
ment was finished within 2 weeks [17,18]. The median
BED on FSRT was 28 Gy (range, 10.1-44.8 Gy). Table 2
summarizes the FSRT treatment parameters.
Follow-up after FSRT
All patients were followed in our clinic every 3 months
for the first 2 years, every 6 months for 3–5 years, and
annually thereafter. MRI of nasopharynx and neck, and
flexible nasopharyngoscopy were routinely performed
during follow-up visits, and suspected lesion was subject
to a biopsy. Blood chemistry panels, serum chemistries,




















Figure 2 Local failure-free survival, overall survival and disease
free survival after FSRT.
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scans were performed annually or if clinically indicated.
End points and statistical analysis
The following endpoints were examined: response to
FSRT, local failure-free survival (LFFS), overall survival,
disease free survival (DFS), and freedom from distant
metastasis (FFDM). Treatment response was evaluated
by fibroendoscopy and MRI scans at six months after
completion of FSRT. Treatment response was evaluated
by imaging studies in most patients. If imaging studies
were nondiagnostic, tissue biopsy would be mandatory if
it was feasible. Complete response (CR) was defined as
complete regression of tumor assessed on MRI and
nasopharyngoscopy or a negative biopsy in patients with
suspected lesions on imaging studies. Partial response
(PR) was defined as tumor regression more than 50% of
bi-dimensional diameters compared to lesions on base-
line images, and no response if neither PR nor CR was
achieved. In-field recurrence was defined as tumor re-
lapse within the volume encompassed by FSRT prescrip-
tion isodose line, and out-of-field recurrence as tumor
relapse outside FSRT target volume but within the pri-
mary EBRT fields. Time was measured from the date
when FSRT completed until time of event occurrence, or
most recent follow-up for censored observations. Actual
incidences of LFFS, OS, DFS and FFDM were calculated
using the Kaplan-Meier method, and the differences be-
tween survival curves were compared using the log–rank
test. Log-rank analysis was used to compare prognostic
factors for LFFS, OS, DFS and FFDM, and factors found
to influence prognosis on univariate analysis were sub-
jected to multivariate analysis using Cox’s proportional
hazard regression model, in order to determine if these
factors acted independently. According to previous
literature [19-22], gender, age(≤45 years vs. >45 years),
interval between primary radiotherapy and FSRT(≤2
months vs. >2 months), T stage (T1–2 vs. T3–4) and N
stage (N0–1 vs. N2–3) at diagnosis, tumor volume
(≤10mL vs. >10 mL), BED(≤30 Gy vs. >30 Gy) and
concurrent chemotherapy use during primary RT were
analyzed as covariates in univariate and multivariate ana-
lyses. All statistical analysis was performed using the
commercial software package SPSS 15.0 (SPSS Institute
Inc., Chicago, USA). All acute and late complications
were scored according to the Common Terminology
Criteria (CTC) for Adverse Events v3.0 criteria and Rad-
iation Therapy Oncology Group (RTOG) criteria.
Results
Treatment results
The median follow-up for all patients was 66.5 months
(range, 10–139). The median follow-up for patients
who were alive was 69 months (range, 20–139). At sixmonths after completion of FSRT, the actuarial CR rate
was 72.1% and PR rate was 23.5%, with an overall re-
sponse rate of 95.6%.
Three- and 5-year LFFS and FFDM rates for all pa-
tients were 94.5 %, 92.5%, and 84.3 %, 77.0%, respectively
(Figure 2). Three- and 5-year OS and DFS rates for all
patients were 85.7 %, 76.2%, and 79.0 %, 73.6%, respec-
tively. During follow-up, local relapse developed in 12
patients: 4 were in-field that occurred in 16–28 months,
and 8 were out-field that occurred in 42–102 months
after FSRT. Five patients developed cervical nodal recur-
rences, and they were salvaged by neck dissection and
were nodal disease free since after. The median local re-
lapse time after FSRT was 35 months (range, 16–102).
Distant metastases (DM) were observed in 36 patients
(26.5%) with a median time of 9 months (range, 1–110
months). The most common sites were the bones (24
patients), lungs (14 patients), and liver (8 patients). Ten
patients developed more than one metastatic site. Of the
patients who developed distant metastases, 6 had initial
Stage IIb, 18 had Stage III, and 12 had Stage IV disease.
Four patients had N0, 12 had N1, 15 had N2, and 5 had
N3 disease. One patient had T1, 11 had T2, 15 had T3,
9 had T4 disease. For stage I/II and stage III/IV patients,
5-year LFFS, OS and DFS rates were 89.9% and 93.3%
(p=0.577), 86.3% and 70.7% (p=0.0.097), 83.2% and
70.8% (p= 0.455), respectively (Figure 3). The cause of
death was distant metastases in 22 patients, local recur-
rence with dyscrasia in 6 patients, postoperative severe
dysphagia and dyscrasia in 1 patient, massive nasopha-
ryngeal hemorrhage in 5 patients, other causes in 12 pa-
tients (including dyscrasia, cerebral hemorrhage and
non-radiation induced pneumonia).
Prognostic factors
Univariate analyses revealed that age (80.5% for pa-
tients ≤45 years vs. 70.7% for patients >45 years, p = 0.042)
was a significant prognostic factor to predict 5-year












































Figure 3 LFFS (a), OS (b) and DFS (c) after FSRT according to
UICC stage.
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≤2 months 78.5 74.7
>2 months 49.7 59.3
p=0.40 p=0.925













≤30 Gy 80.3 73.8
>30 Gy 68.9 72.9
p=0.415 p=0.968
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significant for 5-year actuarial overall survival (83.9%
for T1–2 vs. 70.1% for T3–4, p = 0.039) and disease
free survival (86.2% for T1–2 vs. 63.6% for T3–4,
p =0.039). No other variables were found to be significant
prognostic factors for OS, DFS, LFFS and FFDM. The
results of univariate analyses of OS and DFS are summa-
rized on Table 3. Multivariate analyses showed that age
and T stage at diagnosis were the significant independentprognostic factors for 5-year overall survival (p = 0.034
and p = 0.033, respectively), and T stage at diagnosis
was significant independent prognostic factors for 5-year
disease free survival (p = 0.043). The results of multi-
variate analysis are summarized on Table 4.
Toxicity
There were no severe acute toxicities secondary to
FSRT. All 136 patients completed the full course of
FSRT as planned and treatment was well tolerated. Late
toxicities included cranial nerve injury (IX-XII, grade 1–2)
Table 4 Significant prognostic factors on multivariate
analysis
Covariate B HR P value 95% CI
Overall survival
Age 0.655 1.926 0.034 1.049-3.536
T stage at diagnosis 0.698 2.009 0.033 1.058-3.814
Disease free survival
T stage at diagnosis 0.646 1.907 0.043 1.019-3.570
CI confidence interval, HR hazard ratio.
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asymptomatic temporal lobe necrosis in 6 patients. The
diagnosis of temporal necrosis was all made according to
magnetic resonance spectroscopy. Temporal lobe necrosis
did not affect their job performance or daily life in these
patients.
Discussion
In 2006, we reported a 10-year OS of 66.5% for NPC pa-
tients [23], which was much higher than the earlier his-
torical data reported by Qin et al. (5-year OS: 47.9%)
[24]. One important reason to explain the improving
treatment outcome is the dose escalation by boosting
additional radiation to the residual primary lesions. Al-
though some residual lesion might resolve without boost
dose radiation, patients with residual NPC had a higher
risk of local recurrence, and therefore additional doses
for these patients have improved LC and OS [25,26].
Several other studies demonstrated that there was a
dose–response relationship of NPC above tumoricidal
levels [27,28]. As such, the boost radiation has become a
standard salvage treatment modality for residual NPC in
our institution.Table 5 Clinical outcomes of SRS/FSRT for local persistent NP
Author Number of cases Modalities
Chang et al. (1999) [29] 23 (P) SRS
Tate et al. (1999) [30] 23 (P) SRS
Ahn et al. (2000) [31] 19 (B) FSRT
Xiao et al. (2001) [32] 32 (P) FSRT
Le et al. (2003) [19] 45 (P) SRS
Chua et al. (2003) [33] 7 (P) SRS
Wu et al. (2007) [20] 34 (P) FSRT
Hara et al. [33] (2008) 82 (B) SRS
Present study 136 (P) FSRT
P persistent lesions, B boost, LMN local mucosal necrosis, FNH fetal nasopharyngealOne of the approaches to boost radiation dose for re-
sidual tumor is FSRT. A number of retrospective studies
on using SRS or FSRT after primary EBRT for residual
NPC have been reported, but the numbers of patients
were small or the follow-up time was short (Table 5).
A review of these reports suggests that FSRT improves
the LC and OS of NPC with local residual lesions
[19,20,29-34]. Chua et al. [35] treated 48 local failure
NPC patients using SRS with a median dose of 12.5 Gy,
and the 5-year LFFS and OS rate were 47.2% and 46.9%,
respectively. Dhanachai et al. [21] treated 32 patients
with residual or recurrent NPC using FSRT at a total
dose of 17 to 59.4 Gy (4 to 25 fractions), the 3-year local
progression-free rate and OS rate were 37.9% and 71.2%,
respectively. Chen et al. [36] treated 64 patients with
FSRT of 12–15 Gy, and the 3-year LC and OS rate were
93.1% and 84.9%, respectively. Our study demonstrated
excellent LC and survival in the patients treated with
SFRT for residual disease. Interestingly, with using FSRT
for residual tumors, no statistical significance can be ob-
served in LFFS, DFS and OS in patients with stage I/II
versus stage III/IV disease.
Analysis of our data helped us optimize FSRT regi-
mens for residual NPC. Before April 2006, cranial nerve
injury and massive nasopharyngeal hemorrhage were ob-
served in 8 and 5 patients. Since August 2006, we cau-
tiously adjusted the FSRT regimens. To avoid severe
neurovascular complications, the guidelines of lower
total dose of 10–21 Gy and fractional dose of 2.5-4 Gy
(with a BED ≤27.3 Gy) were used with following indica-
tions: small tumor volume (≤30 cm3), residual tumors
abutting carotid sheath or invading pharyngeal recess,
cavernous sinus or foramen lacerum, IMRT as primary
RT, short interval between primary RT and FSRT (≤2
months), age<15 or>70, and concurrent chemotherapyC in the literature
Dose Results Major complications
7-15 Gy 2-y LC 100% no
7-15 Gy 2-y LC 100% no
8-40 Gy/4-20 f 4-yr LC 89% LMN 1 (5.3%)
4-yr OS 75%
14-24 Gy/2-4 f 3-y DFS 74% FNH 2 (6%)
3-yr OS 70%
7-15 Gy 3-y LC 100% CNI 4 (8.9%)
3-y OS 75% TLN 3 (6.7%)
11-14 Gy 2-y LC 100% no
18 Gy/3 f 3-y LC 89.4% TLN 3 (8.8%)
3-y DFS 80.7%
7-15 Gy 5-y OS 69% TLN 10 (12.2%)
8-32 Gy/2-8 f 5-y DFS 73.6% CNI 8 (5.9%)
5-y OS 76.2% TLN 6 (4.4%)
FNH 5 (3.7%)
hemorrhage, CNI cranial nerve injury, TLN temporal lobe necrosis.
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any features mentioned above, we tended to deliver rela-
tively higher total dose of 15–24 Gy (3–4 Gy per fraction
with BED ≤33.6 Gy) in order to achieve satisfactory
tumor control. The indications for high dose were larger
tumor volume (>30 cm3), residual tumors not abutting
carotid sheath, pharyngeal recess, cavernous sinus or
foramen lacerum. Other indications for higher total dose
included conventional EBRT, relatively long interval be-
tween primary RT and FSRT (>2 months), age 15 to 70,
and those who did not receive concurrent chemotherapy.
On analyzing the prognostic factors, we found that T
stage at diagnosis was a significant independent pre-
dictor of OS and DFS, age was significant prognostic
factor for OS. Our results are consistent with previous
studies [19,22]. Chua et al. [22] reported that T stage,
tumor volume and time interval form primary radiother-
apy were significant predictive factors of LC and survival
whereas age was of marginal significance in predicting
survival. On the other hand, Le et al. [19] reported that
age was significant prognostic factor for survival. Our
data showed no benefit of adding chemotherapy in NPC
patients who received FSRT, which is in concordance
with Le et al.’s and Wu et al.’s study [19,20]. In this
retrospective study, only advanced stage NPC were
treated with chemotherapy but not early stage disease,
so the entire group disease local control and survival
benefits from chemotherapy might have been reduced or
weakened. To address the role of chemotherapy in pa-
tients who received additional FSRT, a phase III random-
ized study should be conducted.
Dhanachai et al. [21] reported significantly worse LC
in patients receiving chemotherapy, but the author
stated that it was not possible to conclude that chemo-
therapy led to the poor LC because there were selection
factors which could lead to the worse outcome. In our
study, tumor volume was not a significant independent
predictor. The prognostic impact of tumor volume was
not concordant with previous studies. Chua et al. [22]
reported significant association between tumor volume
and LC or survival. Wu et al. [20] reported that tu-
mor volume was a significant predictor of progression-
free survival (PFS) and distant metastasis-free survival
(DMFS) but not LFFS, While Dhanachai et al. [21]
reported that chemotherapy was the only significant fac-
tor for local PFS.
Radiation-induced nasopharyngeal necrosis and mas-
sive hemorrhage are consequential late effects in patients
with NPC [37]. The mortality reported for massive naso-
pharyngeal hemorrhage in residual or recurrent NPC
after FSRT is from 16.0% to 22.2% [20,21,32,35].
In 2001, we reported 8 of 50 patients died of fatal
hemorrhage after FSRT [32], and thereafter, we reduced
the fractionated dose. In this study, 5 patients developedmassive nasopharyngeal hemorrhage, but two of them
were treated in 2000 to a total dose of 23–25 Gy at
5.0-5.75 Gy per fraction. The 3 other patients were
treated with FSRT between August 2004 and April 2006,
to a total dose of 14–16 Gy at 3.5-4.0 Gy per fraction.
These 3 patients had primary tumor abutting the carotid
artery, combined with nasopharyngeal infection and ul-
ceration. Massive nasopharyngeal hemorrhage has not
been observed since we carefully chose lower fraction-
ated dose (≤3 Gy per fraction) in patients who had high
risk hemorrhage factors, controlled nasopharyngeal in-
fection, and support patients’ nutrition. Other factors
predicting potential risk of fatal hemorrhage include
high cumulative dose of FSRT and EBRT, previous naso-
pharyngeal brachytherapy and nasopharyngeal necrosis
or infection. Preventive management for nasopharyngeal
necrosis that was used in our study included daily naso-
pharynx douche, nasal oily drops and epithelial growth
factor for healing the ulceration.
Before 2006, 8 patients were observed symptomatic
cranial nerve injuries (5.9%), including 5 hypoglossal
nerve injury (3.7%), and 3 unilateral vocal cord paralyses
(2.2%).
The FSRT regimens included 24 Gy in 4 fractions
(3 patients), 18 Gy in 3 fractions (4 patients), 19.5 Gy in
3 fractions (1 patient). All cranial nerve injuries were on
the same side of the residual lesions that were treated
with FSRT. These patients had residual tumor involving
parapharyngeal space or abutting the carotid artery, it
was difficult for FSRT to completely avoid neurovascular
bundles. In addition, higher fractional dose (≥6Gy) could
be a factor causing cranial nerve injury. Since August
2006, we used revolving conformal MLC-based FSRT,
with reduced fractionated dose (≤4 Gy) and low irradi-
ation dose to carotid sheath (less than 2 Gy per fraction)
for patients with high risk of cranial nerve injury. We
have observed 6 patients (4.4%) developed temporal lobe
necrosis following FSRT, which was probably secondary
to primary conventional radiotherapy; and the FSRT
dose delivered to temporal lobe on these patients was
relatively low. In our experience, FSRT did not exceed
expected mucous membrane toxicity, no more than
grade 2 toxicities had been observed. With the increas-
ing use of dose escalation, and improvements in disease
local control and long-term survival, avoiding potential
late neurovascular injuries has become a priority.
Since the completion of the Intergroup 0099 trial,
which demonstrated improved LC control and survival
with concurrent chemoradiotherapy, this has become a
widely accepted treatment for patients with locoregional
advanced NPC [38]. Although the use of cisplatin-based
concurrent chemoradiotherapy was associated with a
higher LC, many still failed distantly, and survival be-
comes highly dependent on distant control. There were
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lure after FSRT, while DM was still the major relapse
form in this group. Wu et al. [20] reported that the
DMFS rate was 80.8% and 67.2% respectively in residual
and recurrent patients after FSRT. Twenty-two patients
(25.3%) developed DM 3 to 8 months after FSRT, with
relapse of nasopharynx or local lymph nodes in 5 pa-
tients. Le et al. [19] reported a 3-year distant-metastasis
rate of 31.1% (14/45) after SRS. Hara W et al. [34]
treated 82 NPC patients (57% stage IV) using SRS boost
after 66Gy of EBRT, and the 5-year FFDM rate was 68%.
In our study, the 3-year FFDM rate was similar to Wu et
al’s results, while the 5-year FFDM rate was higher than
Hara W et al’s results, probably attributing to the higher
EBRT dose and less proportion of patients in stage IV in
our study. With improved LC, the predominant site of
failure is distant, and more effective systemic treatment
is needed in these patients.
Based on our experience, a total dose of 15 Gy at 3 Gy
per fraction seems to be optimal for satisfactory tumor
local control and reduce the risk of severe neurovascular
complications. For patients with small tumor volume
(≤30 cm3), short interval between primary RT and FSRT
(≤2 months), primary IMRT, or high risk complication
features (residual tumor abutting neurovascular struc-
tures, age<15 or >70, concurrent chemotherapy during
previous RT), we recommended FSRT with a total dose
of 12 Gy at 3 Gy per fraction. Relatively higher total dose
has been used in our practice for those with large tumor
volume (>30 cm3), long interval between primary RT
and FSRT (>3months), primary conventional EBRT, no
risk complication features. The recommended FSRT
regimen for those patients was generally 12–15 Gy (no
more than 21) at 3 Gy per fraction.
Conclusion
In summary, our results indicated that FSRT following
definitive RT or chemoradiation is an effective treatment
modality for patients with residual NPC. This study reit-
erates that FSRT provided satisfactory tumor control
and DFS with acceptable toxicities. Distant metastases
still represent the major causes of failure. Although our
study was limited by the retrospective nature, the out-
comes are encouraging, and further prospective random-
ized study should be conducted to better define the role
of treatment outcome and optimal FSRT fractionations.
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